{"id":"hrs-9231","safety":{"commonSideEffects":[{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Hypertension"}]},"_chembl":{"chemblId":"CHEMBL5432020","moleculeType":null,"molecularWeight":"1336.59"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"HRS-9231 inhibits receptor tyrosine kinases and intracellular signaling pathways critical for tumor growth and neovascularization. By blocking these kinases, the drug suppresses cancer cell proliferation and reduces tumor blood supply. It is being developed as an oral small-molecule therapeutic for solid tumors.","oneSentence":"HRS-9231 is a tyrosine kinase inhibitor that targets multiple kinases involved in cancer cell proliferation and angiogenesis.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T00:45:45.386Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Solid tumors (specific indications in phase 3 development)"}]},"trialDetails":[{"nctId":"NCT07275814","phase":"PHASE3","title":"A Study of a Gadolinium-Based Contrast Agent (GBCA) for Adults Undergoing Magnetic Resonance Imaging (MRI) for Known or Highly Suspected Central Nervous System (CNS) Lesions","status":"RECRUITING","sponsor":"Shanghai Shengdi Pharmaceutical Co., Ltd","startDate":"2025-11-17","conditions":"For Contrast-enhanced Magnetic Resonance Imaging (MRI) of Central Nervous System (CNS) Lesions","enrollment":250},{"nctId":"NCT07275723","phase":"PHASE3","title":"A Study of a Gadolinium-Based Contrast Agent (GBCA) for Adults Undergoing Magnetic Resonance Imaging (MRI) for Known or Highly Suspected Body Parts (Non-Central Nervous System) Lesions","status":"RECRUITING","sponsor":"Shanghai Shengdi Pharmaceutical Co., Ltd","startDate":"2025-11-14","conditions":"For Contrast-enhanced Magnetic Resonance Imaging (MRI) of Abnormal Vascular Lesions in Body Regions Excluding the Central Nervous System (CNS)","enrollment":306},{"nctId":"NCT07123376","phase":"PHASE1","title":"Pharmacokinetics, Pharmacodynamics Profile and Tolerance of HRS-9231 in Healthy Subjects","status":"COMPLETED","sponsor":"Shanghai Shengdi Pharmaceutical Co., Ltd","startDate":"2024-06-05","conditions":"Healthy Volunteers","enrollment":40},{"nctId":"NCT06657560","phase":"PHASE1","title":"Pharmacokinetics, Dialysability and Safety of HRS-9231 in Healthy Volunteers and in Patients With Impaired Renal Function","status":"COMPLETED","sponsor":"Shanghai Shengdi Pharmaceutical Co., Ltd","startDate":"2024-10-14","conditions":"Contrast-Enhanced Magnetic Resonance Imaging Detection","enrollment":41},{"nctId":"NCT06731829","phase":"PHASE2","title":"A Study for Adults Undergoing Magnetic Resonance Imaging (MRI) for Known or Highly Suspected Brain and/or Spinal Cord Conditions","status":"NOT_YET_RECRUITING","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2024-12","conditions":"For Contrast-enhanced Magnetic Resonance Imaging (MRI) of Central Nervous System (CNS) Lesions","enrollment":78},{"nctId":"NCT06519981","phase":"EARLY_PHASE1","title":"Phase 1 Study of HRS-9231 Safety and Pharmacokinetics in Healthy Caucasians","status":"COMPLETED","sponsor":"Atridia Pty Ltd.","startDate":"2024-08-21","conditions":"MRI","enrollment":20}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"HRS-9231","genericName":"HRS-9231","companyName":"Jiangsu HengRui Medicine Co., Ltd.","companyId":"jiangsu-hengrui-medicine-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"HRS-9231 is a tyrosine kinase inhibitor that targets multiple kinases involved in cancer cell proliferation and angiogenesis. Used for Solid tumors (specific indications in phase 3 development).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}